Shared Decision-Making Practices in RSV

The first real-world study highlights benefits for adults aged 60 years and older who receive the respiratory syncytial virus (RSV) vaccine.

A new survey highlights lack of awareness about respiratory syncytial virus (RSV) among older adults, posing increased health risks for those with chronic conditions.

An 18% reduction in acute care encounters for respiratory tract infections among infants 8 weeks or younger was identified following the implementation of New York's paid family leave policy.

A recent study estimates the prevalence of primary care and emergency department visits by young children to treat respiratory syncytial virus (RSV), finding that the rates vary widely by country.

The respiratory syncytial virus (RSV) vaccine shows strong immunogenicity and safety in immunocompromised adults, study finds.

CDC’s Advisory Committee on Immunization Practices (ACIP) revises respiratory syncytial virus (RSV) vaccination guidelines to prioritize older adults and those at higher risk of severe disease.